Meet

CRAIG

a patient with ASTHMA

40-year-old adherent on a MEDIUM-DOSE ICS/LABA

Lungs icon

40-year-old adherent on a
MEDIUM-DOSE ICS/LABA

Lungs icon

a

 
 
 

Unmet need in ASTHMA

You may have patients who remain symptomatic with current therapy.

Asthma symptoms icon

Of patients with ASTHMA treated with a medium- or high-dose ICS/LABA,

30% - 50%

reported inadequately controlled ASTHMA (ACT ≤19), even
when treatment adherence was optimal.1-5*

Based on data from 3 randomized controlled trials (N=2431) and a real-world study (N=428). For the randomized controlled trials, >90% of patients were at least 80% adherent. For the real-world study, only patients with self-reported moderate to high adherence according to the Morisky Medication Adherence Scale were included.1-5

 

See how much TRELEGY improved lung function in adult patients with ASTHMA.

See head-to-head data

 

Which component of TRELEGY inhibits bronchoconstriction?

View MOA triple action

 

What is the starting dose of TRELEGY for adult patients with ASTHMA?

See dosing considerations

Request TRELEGY savings offers for eligible patients & TRELEGY samples.

Learn more